Slides From Hot Topics in NASH: Emerging Treatment Approaches

Learn about the agents in late-phase clinical trials and their potential use in treatment.
Juan Pablo Frias, MD, FACE
Philip N. Newsome, PhD, FRCPE
Format: Microsoft PowerPoint (.ppt)
File Size: 1.73 MB
Released: January 28, 2020


Provided by the American Gastroenterology Association.

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Gilead Sciences
Intercept Pharmaceuticals, Inc.

Related Content

Unlocked slides from Stephen A. Harrison, MD, and CCO: Phase 2&3 drugs in NASH, effects on fibrosis, metabolic state, glycemic control, atherogenic risk

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Released: July 20, 2021

Video from Clinical Care Options (CCO) and Stephen A. Harrison, MD: Emerging treatments for NASH and measuring hepatic and extrahepatic outcomes

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: July 20, 2021 Expired: July 19, 2022

Unlocked slides from Giada Sebastiani, MD and CCO: Role of diet, exercise, and current treatments for NASH

Giada Sebastiani, MD Released: June 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.